Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | See Remarks | January 26, 2018 | January 31, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date January 26, 2018 · Filed January 31, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 4,893 |
Ending reported balance
After 2018-01-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-01-26 · Exercise / conversion · Acquired 7,500 · Balance 7,500 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 2 · 2018-01-26 · Sale · Disposed 2,607 · Balance 4,893 |
| RESTRICTED STOCK UNITSSEC Table II · derivative / convertible security | Direct | 30,000 |
Reported balance
After 2018-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-01-26 · Exercise / conversion · Disposed 7,500 · Balance 30,000 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020. |
| STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2028-01-29 | Direct | 95,000 |
Reported balance
After 2018-01-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-01-30 · Grant · Disposed 95,000 · Balance 95,000 F3: The Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020.
F3: The Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2018 Filed Jan 31, 2018 01:58 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 95,000 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0000899243-18-002328 · doc4.xml · derivative · entry 4 Trucksis Michele · CIK 0001643736 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: COMMON STOCK · 95,000 shares Expires 2028-01-29 F3 · derivative.exercise_date: The Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 26, 2018 Filed Jan 31, 2018 01:58 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002328 · doc4.xml · derivative · entry 3 Trucksis Michele · CIK 0001643736 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: COMMON STOCK · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020. F2 · derivative.expiration_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020. Read SEC document |
| January 26, 2018 Filed Jan 31, 2018 01:58 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 2,607 | $11.02 | $28,729.14 |
DisclosureSEC source: 0000899243-18-002328 · doc4.xml · nonDerivative · entry 2 Trucksis Michele · CIK 0001643736 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,893 Read SEC document |
| January 26, 2018 Filed Jan 31, 2018 01:58 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002328 · doc4.xml · nonDerivative · entry 1 Trucksis Michele · CIK 0001643736 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:51 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-002121 · doc4.xml · derivative · entry 2 Trucksis Michele · CIK 0001643736 · Chief Medical Officer and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020. F3 · derivative.expiration_date: These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:51 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0000899243-17-002121 · doc4.xml · derivative · entry 1 Trucksis Michele · CIK 0001643736 · Chief Medical Officer and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on January 26, 2018. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.